Abstract
In their letter, Locasale and Zeskind hypothesize that anti-interleukin (IL)-6 therapies may be of most benefit in patients with cancer who have low levels of epidermal growth factor (EGF) signaling in their tumors and also that a combination of anti-IL-6 and EGF receptor (EGFR) inhibitors might have clinical benefit in those patients where high EGFR signaling drives the disease. Their hypothesis is based on the following findings:Locasale and Zeskind have made an interesting connection that is worthy of further study. However, there are a number of complexities that may influence the potential association between IL-6 and EGFR signaling in cancer.See the original Letter to the Editor, p. 7837No potential conflicts of interest were disclosed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
